UBS Group AG Purchases 1,405,981 Shares of Novavax, Inc. $NVAX

UBS Group AG raised its position in Novavax, Inc. (NASDAQ:NVAX) by 40.3% in the 4th quarter, Holdings Channel.com reports. The firm owned 4,894,284 shares of the biopharmaceutical company’s stock after buying an additional 1,405,981 shares during the period. UBS Group AG’s holdings in Novavax were worth $32,890,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Shah Capital Management raised its position in shares of Novavax by 23.3% during the fourth quarter. Shah Capital Management now owns 14,558,780 shares of the biopharmaceutical company’s stock worth $97,835,000 after acquiring an additional 2,747,000 shares during the last quarter. Allianz Asset Management GmbH raised its position in shares of Novavax by 162.6% during the third quarter. Allianz Asset Management GmbH now owns 1,409,734 shares of the biopharmaceutical company’s stock worth $12,222,000 after acquiring an additional 872,987 shares during the last quarter. Farallon Capital Management LLC raised its position in shares of Novavax by 4,775.0% during the third quarter. Farallon Capital Management LLC now owns 780,000 shares of the biopharmaceutical company’s stock worth $6,763,000 after acquiring an additional 764,000 shares during the last quarter. Jump Financial LLC bought a new position in shares of Novavax during the third quarter worth about $3,874,000. Finally, HRT Financial LP raised its position in shares of Novavax by 191.8% during the second quarter. HRT Financial LP now owns 615,649 shares of the biopharmaceutical company’s stock worth $3,878,000 after acquiring an additional 404,676 shares during the last quarter. 53.04% of the stock is currently owned by institutional investors.

Key Headlines Impacting Novavax

Here are the key news stories impacting Novavax this week:

• Positive Sentiment: Novavax’s first-quarter results beat expectations, helping fuel a sharp rerating in the stock as investors responded to better-than-expected revenue and earnings performance. Article Title
• Positive Sentiment: The company said patients were “twice as likely” to choose Novavax’s COVID shot over Moderna’s in a recent comparison, adding to optimism around its vaccine positioning. Article Title
• Positive Sentiment: Unusually large call-option buying suggests traders are positioning for further upside in Novavax (NVAX), with options volume far above normal.
• Neutral Sentiment: Novavax also announced it will participate in the BofA Securities 2026 Health Care Conference, which may give management another venue to update investors on strategy and partnerships. Article Title
• Neutral Sentiment: TD Cowen reiterated a $9 price target, which is supportive but not a major new catalyst. Article Title

Analyst Ratings Changes

A number of brokerages have recently issued reports on NVAX. Weiss Ratings downgraded Novavax from a “hold (c-)” rating to a “sell (d)” rating in a research report on Thursday. Wall Street Zen upgraded Novavax from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. BTIG Research restated a “buy” rating and set a $19.00 price objective on shares of Novavax in a research report on Tuesday, January 20th. TD Cowen raised their price objective on Novavax from $8.00 to $9.00 and gave the stock a “hold” rating in a research report on Wednesday. Finally, B. Riley Financial restated a “buy” rating on shares of Novavax in a research report on Thursday, April 9th. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and four have issued a Sell rating to the stock. Based on data from MarketBeat, Novavax currently has an average rating of “Hold” and a consensus target price of $12.13.

Novavax Price Performance

Shares of NVAX opened at $10.11 on Friday. The business has a 50-day moving average of $9.05 and a 200-day moving average of $8.20. Novavax, Inc. has a 1 year low of $5.80 and a 1 year high of $11.97. The company has a market capitalization of $1.66 billion, a price-to-earnings ratio of -17.43 and a beta of 2.37.

Novavax (NASDAQ:NVAX) last released its earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.19. Novavax had a negative return on equity of 14.82% and a negative net margin of 14.73%.The business had revenue of $118.90 million during the quarter, compared to analysts’ expectations of $79.81 million. During the same quarter last year, the firm posted $2.93 earnings per share. The firm’s revenue was down 79.0% on a year-over-year basis. As a group, sell-side analysts anticipate that Novavax, Inc. will post -0.11 EPS for the current year.

Novavax Profile

Novavax, Inc is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases. Founded in 1987, the company has built a platform based on recombinant nanoparticle technology and its proprietary Matrix-M™ adjuvant to enhance immune responses.

The company’s lead product is NVX-CoV2373, a protein-based vaccine designed to elicit a robust immune response against the SARS-CoV-2 virus.